Norway-based clinical-stage biotechnology company Ultimovacs (OSE:ULTI) announced on Monday that it has received Fast Track designation from the US Food and Drug Administration (FDA) for its UV1 therapeutic cancer vaccine.
This designation was granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma, including those in the first-line setting, to improve overall survival. The FDA's decision was based on positive results obtained in the Phase II clinical trial NIPU, which demonstrated improved survival rates when UV1 was administered alongside ipilimumab and nivolumab immunotherapy.
Fast Track status expedites the drug development and review process for serious conditions, allowing Ultimovacs more frequent discussions with the FDA regarding UV1's treatment path for mesothelioma. This designation underscores the potential of UV1 in addressing the urgent medical needs of patients with this challenging cancer type. Mesothelioma, characterised by its aggressiveness and limited treatment options, often arises from asbestos exposure and presents significant challenges in management and care.
UV1 has previously received Orphan Drug Designation for mesothelioma treatment, as well as Fast Track designation as an add-on therapy to ipilimumab or pembrolizumab for the treatment of unresectable or metastatic melanoma.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation